The o~pal CRP Rapid Test

LOW COST The o~pal Reader is 5-200 times cheaper than competitors and the per test cost matches the lowest on the market.
CLINICAL GRADE The o~pal CRP test is objective and fully quantitative
NO TRAVEL The o~pal CRP test can be taken at home and the data sent digitally to a GP or hospital consultant, meaning that people who are not feeling well no longer need to travel, saving the clinician time and minimising the spread of infection in the community.

We are open to partnerships with companies that can accelerate our market entry, including through white-labelling.

éclateral is a digital health/in vitro diagnostics startup developing the most accessible CRP test to guide antimicrobial prescribing.

Two low cost technologies that are already used at scale in diagnostics are combined into a novel testing electrochemical lateral flow test (LFT) platform that relies on electrical measurement, rather than a visual readout.

LFTs now become objective, fully quantitative, multiplexable without the risk of confusion and digitally connected- all while adding <10% to the cost of manufacturing a LFT. The platform uses a low cost (<€30) Reader to power the test and a bespoke App to either report the result to the user, or transmit the result in confidence to a healthcare professional at a remote location.

The Company was established in 2021 and is led by an experienced team including Paul Ko Ferrigno (Founder Avacta Life Sciences and metaLinear; co-Founder Relitect and éclateral, ex-CEO biotIP) and Uroš Zupančič (Novartis, Wyss Institute, ex-CSO biotIP).

The o~pal test platform can be used to develop tests for any analyte for which an antibody pair is available itself. Because the test lines are not visible to the user it is possible to multiplex analytes on a single test strip. We are interested in partnerships that would enable us to include measurements of eg secreted antibiotic resistance markers so that the right antibiotic can be prescribed first time.